Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Authors:
Open Access
- 8 November 2017
- journal article
- practice guideline
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 15 (11) , 1414-1427
Abstract
Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entity separate from HCLvariant (HCLv), which is associated with a more aggressive disease course and may not respond to standard HCL therapies. Somatic hypermutation in the IGHV gene is present in most patients with HCL. The BRAF V600E mutation has been reported in most patients with classic HCL but not in those with other B-cell leukemias or lymphomas. Therefore, it is necessary to distinguish HCLv from classic HCL. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of classic HCL.Keywords
This publication has 43 references indexed in Scilit:
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaNew England Journal of Medicine, 2015
- Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP ChemotherapyJAMA, 2014
- High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemiasNature Genetics, 2013
- Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteriaLeukemia Research, 2013
- Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatmentCancer Treatment Reviews, 2011
- An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosineLeukemia, 2004
- Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsLeukemia, 2003
- Treatment of hairy cell leukemia with cladribine(2-chlorodeoxyadenosine) by subcutaneous bolus injection:a phase II studyAnnals of Oncology, 2002
- Alpha-interferon as induction and maintenance therapy in hairy cell leukemia:a long-term follow-up analysisEuropean Journal of Haematology, 2000
- Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCLAnnals of Oncology, 1994